Loncar Cancer Immunotherapy ETF (CNCR)

NASDAQ: CNCR · IEX Real-Time Price · USD
+0.20 (1.36%)
Jan 31, 2023, 4:00 PM EST - Market closed
Assets $22.27M
Expense Ratio 0.79%
PE Ratio n/a
Shares Out 1.50M
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date Dec 29, 2021
Payout Ratio n/a
1-Year Return -24.05%
Volume 8,596
Open 14.62
Previous Close 14.65
Day's Range 14.62 - 14.89
52-Week Low 12.76
52-Week High 19.76
Beta 0.90
Holdings 32
Inception Date Oct 13, 2015

About CNCR

The Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.

Asset Class Equity
Category Health
Region Global
Stock Exchange NASDAQ
Ticker Symbol CNCR
Issuer Website Loncar
Index Tracked Loncar Cancer Immunotherapy

Top 10 Holdings

41.26% of assets
Name Symbol Weight
Janux Therapeutics, Inc. JANX 5.65%
RAPT Therapeutics, Inc. RAPT 5.10%
Iovance Biotherapeutics, Inc. IOVA 4.17%
BeiGene, Ltd. BGNE 4.08%
IGM Biosciences, Inc. IGMS 3.96%
Xencor, Inc. XNCR 3.84%
Allogene Therapeutics, Inc. ALLO 3.65%
CRISPR Therapeutics AG CRSP 3.62%
Merus N.V. MRUS 3.62%
Arcellx, Inc. ACLX 3.57%
View More Holdings


Ex-Dividend Amount Pay Date
Dec 29, 2021 $1.85334 Dec 31, 2021
Dec 30, 2020 $0.28812 Jan 4, 2021
Dec 28, 2017 $0.3502 Jan 2, 2018
Dec 29, 2015 $0.10551 Jan 4, 2016
Full Dividend History


5 Top-Ranked ETFs to Buy at Bargain Prices for 2023

Concerns over higher inflation and rising rates continued to weigh on investors' sentiments. This has provided a compelling opportunity for investors to buy cheap heading into 2023.

3 weeks ago - Zacks Investment Research

5 ETFs Riding High on the Biotech Comeback

Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.

Other symbols: BBCBBPSBIOXBI
7 months ago - Zacks Investment Research

Pharma & Biotech ETFs at One-Month High: Here's Why

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

7 months ago - Zacks Investment Research

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

Other symbols: BBCPFESBIOXBI
1 year ago - Zacks Investment Research

Should Investors Follow Private Equity into Life Sciences?

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new f...

1 year ago - GuruFocus

9 Best Biotech ETFs to Play High-Octane Trends

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

1 year ago - Kiplinger

Best Biotech Stocks & ETFs for mRNA, Gene Editing

Here is what you should know about investing in these life changing technologies.

1 year ago - Zacks Investment Research

Biotech ETFs extend January gains

Biotech exchange-traded funds rallied Monday as investors continued to monitor the sector and its impact on the coronavirus pandemic. The ETFMG Treatments Testing and Advancement ETF gained 4.6% mid-m...

Other symbols: GERMXBI
2 years ago - Market Watch

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

2 years ago - Zacks Investment Research

As U.K. Authorizes Pfizer Vaccine, Biotech ETFs Continue to Rally

Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. b...

Other symbols: IBBXBI
2 years ago - ETF Trends

Biotech ETFs Remain Hot As Investors Await Upcoming Vaccine

Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has...

Other symbols: BBHIBB
2 years ago - ETF Trends

Will Moderna Vaccine News Boost Biotech ETFs?

Monday saw stocks and index ETFs surge, after the announcement from Pfizer that the pharmaceutical giant had a vaccine candidate with an over 90% effectiveness in clinical trials. Now another biotech,...

Other symbols: BBHIBB
2 years ago - ETF Trends

7 Top ETFs That Trumped Last Week's Market Rout

Last week was extremely volatile for Wall Street with the S&P 500, the Dow Jones and the Nasdaq losing about 2.5%, 1.7% and 4.1%, respectively.

Other symbols: DWSHEPHEITB
2 years ago - Zacks Investment Research

6 Sector ETFs Surviving the Market Rout

Amid the uncertainties, a few sectors have survived last week's turmoil. We have highlighted six of that could be compelling picks for the weeks ahead as long as volatility persists.

2 years ago - Zacks Investment Research

5 ETFs Jump After Three-Day Rout: Will The Rally Last?

We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.

Other symbols: ARKQPBWPTH
2 years ago - Zacks Investment Research

Specialty biotech funds jump on promising coronavirus, funding news

Specialized health-care exchange-traded funds outperformed the broader stock market Wednesday even as stocks rebounded from a sell-off that left the Nasdaq Composite Index in correction territory. Th...

Other symbols: PTH
2 years ago - Market Watch

Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data

Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.

2 years ago - Zacks Investment Research

Moderna Vaccine Optimism Could Drive Biotech ETFs

Stock indexes and ETFs rocketed higher and are continuing the uptrend in trading Wednesday after Moderna said its coronavirus vaccine generated antibodies in elderly patients for the first time, creat...

Other symbols: BBHIBBXBI
2 years ago - ETF Trends

6 Best Biotech ETFs to Buy for Cutting-Edge Growth

Biotech ETFs are, in a word, hot.

2 years ago - Kiplinger

7 Biotech ETFs to Buy Now For Covid-19 And Beyond

Biotech ETFs are popular and delivering for investors, but not all of these funds need the Covid-19 pandemic to soar.

2 years ago - InvestorPlace

Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine

Moderna plans to begin the Phase 3 study of mRNA-1273 this month.

2 years ago - Zacks Investment Research

Moderna Study Sends Biotech ETFs And Stock Futures Surging

Stock futures rocketed higher and are continuing the uptrend in overnight trading on Tuesday after Moderna said its coronavirus vaccine generated antibodies in all patients in an early trial, creating...

Other symbols: BBHBTECIBBXBI
2 years ago - ETF Trends

7 ETFs for the End of the Coronavirus

The Covid-19 pandemic dinged a slew of asset classes, but these ETFs are positioned to benefit when the virus is squashed.

2 years ago - InvestorPlace

AstraZeneca Joins Coronavirus Vaccine Race, Great For Biotech ETFs

With the race to find a vaccine for the coronavirus, now drugmaker AstraZeneca is the latest to receive funding to generate a panacea.

Other symbols: AZNBBHIBBXBI
2 years ago - ETF Trends

3 ETFs For More Moderna Bets

Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.

Other symbols: BTECIDNA
2 years ago - Benzinga